Graft Versus Host Disease (GVHD) – Pipeline Review, H1 2012

Graft Versus Host Disease (GVHD) – Pipeline Review, H1 2012


March 19, 2012
347 Pages - SKU: GMD3811062
License type:
Online Download      US $500.00
Global Site License      US $1,500.00
Graft Versus Host Disease (GVHD) – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2012', provides an overview of the Graft Versus Host Disease (GVHD) therapeutic pipeline. This report provides information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD). 'Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Graft Versus Host Disease (GVHD).
  • A review of the Graft Versus Host Disease (GVHD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Graft Versus Host Disease (GVHD) pipeline on the basis of route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Graft Versus Host Disease (GVHD).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Graft Versus Host Disease (GVHD) pipeline depth and focus of Graft Versus Host Disease (GVHD) therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.



More Drug Discovery reports by Global Markets Direct

House Dust Mite Allergy - Pipeline Review, H1 2014 by Global Markets Direct
House Dust Mite Allergy - Pipeline Review, H1 2014SummaryGlobal Markets Direct’s, ‘House Dust Mite Allergy - Pipeline Review, H1 2014’, provides an overview of the ...
Cedar Pollen Allergy - Pipeline Review, H1 2014 by Global Markets Direct
Cedar Pollen Allergy - Pipeline Review, H1 2014SummaryGlobal Markets Direct’s, ‘Cedar Pollen Allergy - Pipeline Review, H1 2014’, provides an overview of the Cedar Pollen ...
Food Allergy - Pipeline Review, H1 2014 by Global Markets Direct
Food Allergy - Pipeline Review, H1 2014SummaryGlobal Markets Direct’s, ‘Food Allergy - Pipeline Review, H1 2014’, provides an overview of the Food Allergy’s therapeutic pipeline.This ...
Bone Marrow Transplantation - Pipeline Review, H1 2014 by Global Markets Direct
Bone Marrow Transplantation - Pipeline Review, H1 2014SummaryGlobal Markets Direct’s, ‘Bone Marrow Transplantation - Pipeline Review, H1 2014’, provides an overview of the Bone Marrow ...
See all reports like this >>